S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:VERU

Veru Stock Competitors

$13.38
-0.91 (-6.37%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$12.66
$14.21
50-Day Range
$4.35
$15.60
52-Week Range
$4.34
$17.50
Volume
11.55 million shs
Average Volume
24.79 million shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.57

Veru (NASDAQ:VERU) Vs. ARWR, GLPG, CERE, ZLAB, BHC, MRTX, CVAC, BPMC, CYTK, and RARE

Should you be buying Veru stock or one of its competitors? The main competitors of Veru include Arrowhead Pharmaceuticals (ARWR), Galapagos (GLPG), Cerevel Therapeutics (CERE), Zai Lab (ZLAB), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), CureVac (CVAC), Blueprint Medicines (BPMC), Cytokinetics (CYTK), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "personal products" industry.These companies are all part of the "pharmaceutical preparations" industry.

Veru vs.

Veru (NASDAQ:VERU) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.

Veru has a beta of -0.57, meaning that its stock price is 157% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Veru currently has a consensus price target of $35.40, indicating a potential upside of 164.57%. Arrowhead Pharmaceuticals has a consensus price target of $72.40, indicating a potential upside of 99.94%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Arrowhead Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veru
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Arrowhead Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

Veru has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Veru is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veru$61.26 million17.49$7.39 million-$0.34-39.35
Arrowhead Pharmaceuticals$138.29 million27.69-$140.85 million-$1.09-33.22

29.1% of Veru shares are held by institutional investors. Comparatively, 64.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 23.1% of Veru shares are held by insiders. Comparatively, 3.5% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals received 236 more outperform votes than Veru when rated by MarketBeat users. However, 70.81% of users gave Veru an outperform vote while only 67.03% of users gave Arrowhead Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
VeruOutperform Votes
262
70.81%
Underperform Votes
108
29.19%
Arrowhead PharmaceuticalsOutperform Votes
498
67.03%
Underperform Votes
245
32.97%

Arrowhead Pharmaceuticals has a net margin of -42.44% compared to Veru's net margin of -45.56%. Veru's return on equity of -18.64% beat Arrowhead Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Veru -45.56% -18.64% -15.67%
Arrowhead Pharmaceuticals -42.44% -26.77% -16.05%

In the previous week, Veru had 20 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 29 mentions for Veru and 9 mentions for Arrowhead Pharmaceuticals. Veru's average media sentiment score of 0.18 beat Arrowhead Pharmaceuticals' score of -0.68 indicating that Veru is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veru
6 Very Positive mention(s)
7 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Arrowhead Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Negative

Summary

Veru beats Arrowhead Pharmaceuticals on 10 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Veru (NASDAQ:VERU) vs. Its Competitors

MetricVeruPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.14B$5.50B$4.32B$5.71B
Dividend YieldN/A2.43%2.02%3.19%
P/E Ratio-39.357.668.9411.12
Price / Sales17.49336.732,413.07102.30
Price / CashN/A20.8722.9283.75
Price / Book7.873.794.034.63
Net Income$7.39M$190.38M$164.30M$240.07M
7 Day Performance2.92%2.07%1.11%0.26%
1 Month Performance11.87%-15.37%-14.06%-11.22%
1 Year Performance64.78%-46.80%-31.00%-26.98%

Veru Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARWR
Arrowhead Pharmaceuticals
1.9255 of 5 stars
$36.21
+3.0%
$72.40
+99.9%
-51.6%$3.83B$138.29M-33.22329Gap Up
GLPG
Galapagos
1.3509 of 5 stars
$56.34
-1.1%
$65.97
+17.1%
-23.7%$3.70B$573.66M0.001,309
CERE
Cerevel Therapeutics
1.8364 of 5 stars
$24.94
+2.0%
$42.17
+69.1%
+77.3%$3.62BN/A-14.58200
ZLAB
Zai Lab
1.9915 of 5 stars
$36.79
+3.0%
$117.50
+219.4%
-77.3%$3.60B$144.31M-6.271,951Gap Up
BHC
Bausch Health Companies
2.6998 of 5 stars
$9.93
-2.2%
$18.75
+88.8%
-68.5%$3.58B$8.43B-8.7119,600
MRTX
Mirati Therapeutics
1.7575 of 5 stars
$63.35
+6.3%
$168.64
+166.2%
-58.8%$3.52B$72.09M-5.32413Analyst Upgrade
News Coverage
Positive News
Gap Up
CVAC
CureVac
1.3815 of 5 stars
$18.73
-3.5%
$53.75
+187.0%
-83.7%$3.50B$115.57M0.00455
BPMC
Blueprint Medicines
2.6214 of 5 stars
$57.37
+0.7%
$103.73
+80.8%
-39.9%$3.42B$180.08M-5.19495Analyst Report
CYTK
Cytokinetics
1.9917 of 5 stars
$39.76
+2.5%
$56.31
+41.6%
+66.8%$3.41B$70.43M-12.35253Insider Selling
Analyst Revision
RARE
Ultragenyx Pharmaceutical
2.2886 of 5 stars
$48.55
+3.3%
$112.15
+131.0%
-56.6%$3.29B$351.41M-7.071,119Analyst Report
KRTX
Karuna Therapeutics
2.5198 of 5 stars
$104.53
+0.4%
$176.22
+68.6%
-11.4%$3.11B$36.96M-18.08118
PCRX
Pacira BioSciences
2.1729 of 5 stars
$63.59
+0.9%
$82.00
+29.0%
-4.1%$2.86B$541.53M75.70697News Coverage
ACAD
ACADIA Pharmaceuticals
2.8113 of 5 stars
$17.11
+1.7%
$29.45
+72.1%
-20.7%$2.76B$484.14M-12.86514
PBH
Prestige Consumer Healthcare
1.8598 of 5 stars
$54.01
+1.4%
$80.50
+49.0%
+8.1%$2.67B$1.09B13.37505
INSM
Insmed
2.0381 of 5 stars
$20.25
+3.5%
$53.00
+161.7%
-22.9%$2.42B$188.46M-5.36373Gap Up
ARVN
Arvinas
2.2953 of 5 stars
$44.64
+1.3%
$105.76
+136.9%
-30.2%$2.37B$46.70M-10.71280Analyst Report
Gap Up
PTCT
PTC Therapeutics
1.8048 of 5 stars
$32.33
-0.5%
$50.75
+57.0%
-17.5%$2.32B$538.59M-4.381,177News Coverage
HRMY
Harmony Biosciences
2.5748 of 5 stars
$41.33
+5.6%
$58.25
+40.9%
+27.2%$2.31B$305.44M51.66180Positive News
Gap Up
FOLD
Amicus Therapeutics
1.9336 of 5 stars
$7.76
+4.6%
$15.14
+95.1%
-15.2%$2.17B$305.51M-8.00496
CORT
Corcept Therapeutics
2.5498 of 5 stars
$20.42
+0.8%
$29.67
+45.3%
-5.3%$2.17B$365.98M22.44238Insider Selling
News Coverage
Negative News
EQRX
EQRx
2.0333 of 5 stars
$4.36
-6.2%
$5.60
+28.4%
N/A$2.13BN/A0.00240Earnings Report
Analyst Downgrade
News Coverage
OPK
OPKO Health
2.3648 of 5 stars
$3.09
+3.3%
$6.00
+94.2%
-16.3%$2.04B$1.77B-17.175,767Insider Buying
Gap Up
SAGE
Sage Therapeutics
2.6134 of 5 stars
$32.53
+2.2%
$60.71
+86.6%
-56.1%$1.88B$6.31M-3.95471Gap Up
TPTX
Turning Point Therapeutics
1.9176 of 5 stars
$36.74
+3.9%
$94.00
+155.9%
-47.8%$1.82B$30.83M-6.61250Analyst Report
Gap Up
GBT
Global Blood Therapeutics
1.9864 of 5 stars
$27.33
+1.8%
$57.27
+109.6%
-27.6%$1.78B$194.75M-5.61457
EBS
Emergent BioSolutions
2.4314 of 5 stars
$35.33
+11.5%
$49.17
+39.2%
-39.8%$1.77B$1.79B12.142,416Gap Up
High Trading Volume
SDGR
Schrödinger
2.0581 of 5 stars
$24.75
+0.1%
$68.50
+176.8%
-61.6%$1.76B$137.93M-13.10664
IRWD
Ironwood Pharmaceuticals
2.4248 of 5 stars
$11.39
-0.6%
$15.00
+31.7%
-8.4%$1.75B$413.75M3.57219
AUPH
Aurinia Pharmaceuticals
1.7971 of 5 stars
$12.05
+3.4%
$25.60
+112.4%
-6.0%$1.71B$45.60M-9.41300
AMPH
Amphastar Pharmaceuticals
2.2148 of 5 stars
$33.70
flat
$36.67
+8.8%
+71.2%$1.65B$437.77M20.931,761Analyst Downgrade
Insider Selling
News Coverage
HCM
HUTCHMED
1.6814 of 5 stars
$9.58
+4.2%
$47.67
+397.6%
-65.5%$1.59B$356.13M0.001,759Gap Up
CCXI
ChemoCentryx
2.0914 of 5 stars
$22.79
+3.4%
$75.00
+229.1%
+126.5%$1.57B$32.22M-11.34178
TVTX
Travere Therapeutics
1.7215 of 5 stars
$24.18
-1.7%
$35.00
+44.7%
+32.9%$1.56B$227.49M-7.39310Analyst Report
Analyst Revision
XENE
Xenon Pharmaceuticals
1.7998 of 5 stars
$29.14
+2.2%
$44.00
+51.0%
+62.9%$1.51B$18.44M-16.28149Options Volume
SUPN
Supernus Pharmaceuticals
1.6864 of 5 stars
$27.48
+1.4%
$44.00
+60.1%
-12.1%$1.47B$579.78M21.14575
TARO
Taro Pharmaceutical Industries
2.1665 of 5 stars
$37.60
+1.4%
$73.00
+94.1%
-47.7%$1.41B$548.97M940.241,417Upcoming Earnings
DVAX
Dynavax Technologies
2.0464 of 5 stars
$10.80
-3.4%
$23.50
+117.6%
+37.9%$1.41B$439.44M19.64311
XNCR
Xencor
2.2 of 5 stars
$23.55
+2.5%
$56.33
+139.2%
-42.3%$1.40B$275.11M13.23254
LGND
Ligand Pharmaceuticals
2.8681 of 5 stars
$82.88
+0.2%
$180.83
+118.2%
-32.9%$1.40B$277.13M60.06154Analyst Upgrade
RCUS
Arcus Biosciences
2.2464 of 5 stars
$18.92
+2.3%
$60.86
+221.7%
-26.8%$1.36B$382.88M34.40366Gap Up
SRRA
Sierra Oncology
2.0848 of 5 stars
$54.75
+0.0%
$51.00
-6.8%
+208.5%$1.34B$300K-8.09109Analyst Upgrade
ME
23andMe
1.5831 of 5 stars
2.88
-1.4%
8.50
+195.1%
N/A$1.31BN/A0.00572Upcoming Earnings
Gap Up
ISEE
IVERIC bio
1.6255 of 5 stars
$11.06
+2.1%
$23.29
+110.5%
+58.0%$1.29BN/A-9.7994Analyst Report
Gap Up
AXSM
Axsome Therapeutics
2.2748 of 5 stars
$31.65
+0.4%
$85.97
+171.6%
-43.0%$1.23BN/A-8.51108
PRTA
Prothena
2.6486 of 5 stars
$27.08
+3.4%
$70.89
+161.8%
+16.9%$1.23B$200.58M22.2082Positive News
Gap Up
RXDX
Prometheus Biosciences
2.1864 of 5 stars
$29.56
+1.9%
$52.88
+78.9%
+44.1%$1.16B$3.13M-10.6372Analyst Revision
News Coverage
AGIO
Agios Pharmaceuticals
1.9942 of 5 stars
$21.10
+2.4%
$51.57
+144.4%
-62.8%$1.16B$203.20M-3.27390Analyst Report
Analyst Revision
CYRX
Cryoport
1.8714 of 5 stars
$23.27
+0.0%
$61.83
+165.7%
-55.6%$1.15B$222.61M-3.81791Analyst Report
Analyst Revision
Gap Up
MDGL
Madrigal Pharmaceuticals
2.4514 of 5 stars
$66.71
-1.7%
$167.43
+151.0%
-48.6%$1.14BN/A-4.5571
BBIO
BridgeBio Pharma
2.7048 of 5 stars
$7.61
+3.0%
$40.83
+436.6%
-86.7%$1.12B$69.72M-1.87576News Coverage
This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.